Sarina Tanimoto Sells 100,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.16, for a total transaction of $1,316,000.00. Following the sale, the insider now owns 1,148,499 shares of the company’s stock, valued at approximately $15,114,246.84. This represents a 8.01 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Sarina Tanimoto also recently made the following trade(s):

• On Tuesday, October 15th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $14.88, for a total transaction of $1,488,000.00.

ARS Pharmaceuticals Stock Up 3.0 %

ARS Pharmaceuticals stock opened at $12.64 on Friday. ARS Pharmaceuticals, Inc. has a twelve month low of $5.02 and a twelve month high of $18.51. The company has a 50 day moving average of $14.67 and a 200-day moving average of $12.32. The stock has a market capitalization of $1.23 billion, a PE ratio of -24.78 and a beta of 0.88.

Institutional Trading of ARS Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in ARS Pharmaceuticals in the 3rd quarter valued at $30,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in ARS Pharmaceuticals by 151.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock worth $63,000 after acquiring an additional 4,472 shares in the last quarter. Principal Financial Group Inc. bought a new stake in ARS Pharmaceuticals during the second quarter worth $87,000. Quarry LP acquired a new position in shares of ARS Pharmaceuticals during the 3rd quarter worth about $174,000. Finally, TFG Advisers LLC bought a new position in ARS Pharmaceuticals during the third quarter worth about $180,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Analyst Ratings Changes

SPRY has been the subject of a number of analyst reports. Leerink Partners lifted their price objective on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research note on Friday, September 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 price objective on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Finally, William Blair raised shares of ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $24.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.